Humira Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials
• Forums

Assessment of Predictive Factors for Persistence of Treatment After Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Conditions:   Crohn Disease;   Ulcerative Colitis;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis Intervention:   Sponsor:   Fresenius Kabi, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 28, 2022 Category: Research Source Type: clinical trials